However, only a small number of studies have evaluated the effects of SGLT2 inhibitors on HF-related clinical parameters, such as NT-proBNP concentration, according to the background use of glucose-lowering medications in patients complicated with HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.